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Protein kinase D 1 (PKD-1) is a signaling kinase important in fundamental cell functions
including migration, proliferation, and differentiation. PKD-1 is also a key regulator of
gene expression and angiogenesis that is essential for cardiovascular development and
tumor progression. Further understanding molecular aspects of PKD-1 signaling in the
regulation of angiogenesis may have translational implications in obesity, cardiovascular
disease, and cancer. The author will summarize and provide the insights into molecular
mechanisms by which PKD-1 regulates transcriptional expression of angiogenic genes,
focusing on the transcriptional regulation of CD36 by PKD-1-FoxO1 signaling axis along
with the potential implications of this axis in arterial differentiation and morphogenesis.
He will also discuss a new concept of dynamic balance between proangiogenic and
antiangiogenic signaling in determining angiogenic switch, and stress how PKD-1
signaling regulates VEGF signaling-mediated angiogenesis.
Keywords: protein kinase D, CD36, VEGF, gene expression, transcription, endothelial cells, angiogenesis,
arteriogenesis
INTRODUCTION
The protein kinase PKD (PRKD) is a serine threonine kinase consisting of three isoforms PKD-1,-2,
and -3 (Rykx et al., 2003; Evans et al., 2010). Different PKD family members have unique and non-
redundant roles. PKD-1 is essential for normal embryogenesis while PKD-2 regulates the functions
of mature peripheral lymphocytes during adaptive immune responses (Matthews et al., 2010) and
PKD-3 modulates airway epithelial barrier formation, the growth of breast and prostate cancer
cells and vesicle trafficking (Anderson et al., 2005; Chen et al., 2008; Huck et al., 2012, 2014).
Initially, PKD-1 was classified to an atypical member of protein kinase C (PKC) family and known
as PKCmu. However, this kinase presents a catalytic domain distantly related to Ca2+-regulated
kinase and it was thus classified to the calcium/calmodulin-dependent protein kinase superfamily
(Manning et al., 2002; Rozengurt et al., 2005).
PKD-1 mRNA is highly expressed in such tissues as the heart, the lungs, and the brain, as well as
in a variety of cell types including vascular endothelial cells (VECs), fibroblasts, and dendritic cells.
This indicates that PKD-1 is a key regulator in tissue homeostasis and cellular functions. PKD-1
mediates signaling pathways important in cardiovascular diseases, immune functions and cancer
(Parra et al., 2005; Fielitz et al., 2008; Ha et al., 2008b; LaValle et al., 2010a,b; Wille et al., 2014). It
may be involved in myocardial responses to ischemia and arterial remodeling (Avkiran et al., 2008;
Ren et al., 2014, 2015). It also regulates cardiac energy homeostasis by influencing the secretion of
cardiac lipoprotein lipase, an enzyme important in controlling heart metabolism in experimental
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diabetes (Wang and Rodrigues, 2015). The studies on lung
microvascular ECs (MVECs) indicate that PKD-1 is required
for PMA- and DAG-induced phosphorylation of myristoylated
alanine-rich PKC substrate and hyperpermeability (Tinsley et al.,
2004).
Interestingly, PRKD1 is likely the gene targeted in clinical
trials for schizophrenia drugs, implicating its functional
significance in the brain functions. The authors suggested that
bryostatin, a partial agonist at PKD, represents a promising
drug for the treatment of schizophrenia (Lencz and Malhotra,
2015). GWAS studies show that PRKD gene is associated
with body mass index (Speliotes et al., 2010; Comuzzie et al.,
2012), suggesting the involvement of PKD-1 signaling in the
pathobiology of diet-induced obesity (Huang et al., 2013; Dong
et al., 2015; Yuan et al., 2015).
In the vascular system, PKD-triggered signaling pathways
in ECs appear to process angiogenic information so that ECs
respond appropriately to the environmental stimuli. This may
be involved in VEGF-stimulated phospholipase Cγ1 (PLCγ1)
signaling (Wong and Jin, 2005; Qin et al., 2006) and LPA-
mediated transcriptional repression of CD36 (Ren et al., 2011).
In this review, the author will briefly introduce the essential
features of PKD-1 in structures and functions. Subsequently, he
will discuss regulation of angiogenic gene expression by PKD-
1 and its biological implications. He will specifically emphasize
how CD36 transcription is regulated by PKD-1-FoxO1 signaling
axis and what this axis implicates in arterial differentiation
and morphogenesis. Finally, he will discuss a new concept
of dynamic balance between proangiogenic and antiangiogenic
signaling in determining angiogenic switch and focus on PKD-1
signaling in the regulation of VEGF-mediated EC functions and
angiogenesis
STRUCTURAL FEATURES AND GENERAL
FUNCTIONS OF PKD-1
PKD is encoded by the PRKD1 gene that is located on
human chromosome14q11. The gene transcript consists of 18
exons, and encodes a protein with 912 amino acid residues.
PKD-1 contains a C-terminal kinase domain and a variable
N-terminal regulatory domain with two highly conserved
FIGURE 1 | Functional domains of PKD-1. PKD-1 contains multiple functional domains including alanine and proline rich domain (APR); cysteine-rich, zinc
finger-like domains (CR1 and CR2); acidic-rich region (AR); and pleckstrin homology domains (PH). There are six conserved phosphorylation sites. In response to a
variety of biological factors, these sites can be phosphorylated to activate PKD-1 and regulate fundamental cellular functions.
cysteine-rich zinc finger-like motifs (CR1 and CR2) and
a pleckstrin homology (PH) domain inserted between the
cysteine-rich motif and the catalytic domain. Different from
protein kinase PKC, PKD contains PH domain within the
regulatory region. The catalytic domain is distantly related
to Ca2+-regulated kinase, and a highly hydrophobic stretch
of amino acids is located in its N-terminal region (Lint et al.,
2002; Rozengurt et al., 2005). The structural characteristics
make this kinase unique in the regulation of cellular
functions through activating its multiple phosphorylation
sites (Figure 1).
PKD-1 remains inactive in cytosol partly through auto-
inhibition of its catalytic activity by the PH domain. The
multisite phosphorylations of the kinase control its signaling
spatiotemporally. The phosphorylation in specific sites changes
the catalytic activity and influences docking interactions with
cellular scaffolds and trafficking to signalingmicrodomains in the
subcellular compartments (Steinberg, 2012). G-protein subunits
βγ directly interacts with the PH domain to activate the kinase
by releasing the auto-inhibition of catalytic domain (Jamora
et al., 1999; Waldron and Rozengurt, 2003). Once PKD-1 is
stimulated by engaging G protein–coupled receptors (GPCRs)
in response to growth factor signaling or oxidative stress, the
molecules are able to be translocated to the plasma membrane.
In the plasma membrane they are phosphorylated and activated.
However, these molecules will ultimately be accumulated in the
nucleus (Matthews et al., 2000) while its subcellular localization
is regulated by the N-terminal domain, and the zinc finger-
like motifs in particular (Rykx et al., 2003). The major catalytic
sites are located at ser-744 and ser-748 or ser-738 and ser-742
within the activation loop of the catalytic domain, respectively
in mouse and human PKD-1 (Iglesias et al., 1998) and in
ser-916 (Matthews et al., 1999; Rozengurt et al., 2005). The
phosphorylation activates PKD-1, whereas binding to 14-3-3
or chaperon protein p32 decreases its activity. Additionally,
in response to apoptosis inducing agents, PKD-1 undergoes
cleavage, releasing a 62 kD catalytic fragment by caspase 3 (Endo
et al., 2000).
PKD-1 signaling functions downstream of PLCγ1, GPCRs,
and tyrosine kinase receptors. The signaling activation
phosphorylates downstream targets at specific sites, thereby
regulating subcellular localization and/or its activity (Rozengurt,
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2011) and the cellular processes such as DNA synthesis,
proliferation, and invasion/migration (LaValle et al., 2010b).
Importantly, PKD-1 signaling locates upstream of PI3K-Akt and
MAPK/Erk1/2 signaling pathways (Guha et al., 2010) and is able
to induce NF-kB activity in cells exposed to GPCR agonists or
oxidative stress (Storz et al., 2005), which implicates the central
roles of this kinase in EC functions and arteriogenesis (Ren et al.,
2010, 2015; Tirziu et al., 2012).
REGULATION OF TRANSCRIPTIONAL
EXPRESSION OF ANGIOGENIC GENES BY
PKD-1
Gene expression controls cellular phenotypes. Different cell types
express characteristic sets of transcriptional regulators, thus
controlling the expression of cellular specific genes through
turning specific combinations of regulators on and off. The
gene regulation drives the processes of cellular differentiation
and morphogenesis to produce different cell types that possess
varying gene expression profiles. The differential expression of
angiogenic genes is critical in EC heterogeneity and angiogenesis
(Adams and Alitalo, 2007; Aird, 2012; Ren, 2015; Yuan et al.,
2016).
More and more studies show that PKD-1 signaling regulates
the transcriptional expression of genes that are important in
angiogenesis. The early growth response 3 (Egr3) is a member
of a zinc-finger-like transcription factor subfamily. VEGF
activates PKD-1 via the VEGFR2/KDR-PKC signaling, and
subsequently induces Egr-dependent transcriptional activation
and Egr3 expression (Liu et al., 2008), whereas inhibition of
Egr3 expression decreases VEGF-mediated EC proliferation,
migration and tubulogenesis (Liu et al., 2008). Recently, Zhao
et al. showed that the calcium-PLC-PKC-PKD-1 pathway
regulates VEGF-induced mRNA expression of TR3-TV2 and
TR3-TV3 (Zhao et al., 2014). PKD-1/HDAC7/MEF2 signaling
together with Erk1/2 pathway also regulates VEGF-induced
Nur77 expression during VEGF-induced EC activation (Ismail
et al., 2012).
PKD-1 Interaction with Histone
Deacetylases to Regulate Angiogenic
Gene Expression
Histone acetylation/deacetylation regulates transcriptional
expression of genes through a dynamic balance between histone
acetyltransferases and histone deacetylases (HDACs). HDACs
are critical to inhibiting acetylation of nucleosome histones.
Interestingly, HDAC5 and HDAC7, highly expressed in ECs
(Mottet et al., 2007; Altschmied and Haendeler, 2008), are
the substrate of PKD-1 (Avkiran et al., 2008) and regulate
EC functions and angiogenesis (Wang et al., 2008; Urbich
et al., 2009). VEGF stimulates HDAC5 phosphorylation and
nuclear export in ECs via a VEGFR2-PLCγ-PKD-dependent
pathway. Moreover, PKD-1 signaling interacts with HDAC5
to promote transcriptional activation of myocyte enhancer
factor-2 (MEF2) and a specific subset of gene expression in
response to VEGF including NR4A1, an orphan nuclear receptor
involved in angiogenesis (Ha et al., 2008b). VEGF-mediated
PKD-1 signaling also stimulates HDAC7 phosphorylation and
cytoplasmic accumulation, thus modulating the expression
of HDAC7-targeting and VEGF-response genes as well as
VEGF-stimulated EC migration, tube formation, and sprouting
angiogenesis (Mottet et al., 2007; Ha et al., 2008a). A similar
mechanism is involved in the induction of PDGF-B/PDGFR-β
expression and subsequent proangiogenic responses (Mottet
et al., 2007). These studies indicate that PKD-1 interacts
with specific HDACs to function as a molecular switch for
controlling angiogenic gene transcription and VEGF-mediated
angiogenesis.
Regulation of Arteriogenic Gene
Expression by PKD-1 in Microvascular
Endothelial Cells
In primary MVECs, the lysophosphatidic acid (LPA), a
lipid signaling mediator, regulates angiogenesis in a chicken
chorioallantoic membrane assay and in vivo Matrigel assay
(Rivera-Lopez et al., 2008; Ren et al., 2011) and promotes
breast cancer angiogenesis in diet-induced obesity (Dong et al.,
2015). LPA/PKD-1 signaling-mediated CD36 transcriptional
repression is important in angiogenic processes (Ren et al.,
2011). We found that PKD-1 signaling in MVECs promotes
nuclear accumulation of HDAC7 in response to LPA (Ren et al.,
2014), which is different from a previous report in HUVECs
exposed to VEGF (Ha et al., 2008a). This indicates that a PKD-
1 signaling “signature” is different in a specific cellular context.
In certain cellular microenvironments, PKD-1 determines the
formation of nuclear regulatory complex and aids in gene locus-
specific nucleosomal enrichment of specific histone deacetylase
(Fu and Rubin, 2011). PKD-1 may mediate HDAC7-FoxO1
interaction in the nucleus (Ren et al., 2014, 2015) and maintain
context relevant EC functions via FoxO1-dependent regulation
of CD36 transcription in HMVECs rather than via MEF-2-
dependent regulation of matrix metalloprotease (Chang et al.,
2006).
HDAC7 is an established regulator of chromatin structure and
gene transcription (Haberland et al., 2009) and of angiogenesis
(Chang et al., 2006; Mottet et al., 2007; Ha et al., 2008a). HDAC7-
regulated gene repression and de-repression are indispensable
for angiogenic functions (Ha et al., 2008a; Wang et al., 2008).
In MVECs LPA/PKD-1 signaling appears to control the FoxO1
transcriptional switch (Hamik et al., 2006) via mediating the
formation of a nuclear complex comprised of FoxO1 and
HDAC7. PKD-1 signaling activation might specifically turn off
the FoxO1 switch in the CD36 gene locus for suppressing
CD36 transcription, whereas arteriogenic gene reprogramming
is initiated once CD36 transcription is turned off in response
to LPA (Ren et al., 2015). This may be associated with
the proarteriogenic responses in a tumor microenvironment
(Kohlenberg et al., 2013). These findings suggest that PKD-1
signaling epigenetically regulates arteriogenic gene transcription
via modulation of chromatin remodeling and is involved in
microvascular remodeling.
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PKD-1 FUNCTIONS IN VEGF SIGNALING
AND ANGIOGENESIS
Basic Concept of Angiogenesis
Angiogenesis is a physiological or pathological process from
which new blood vessels develop from pre-existing vessels,
and in which ECs is the key (Carmeliet, 2000; Semenza,
2007; Ren, 2015). Physiological angiogenesis is fundamental
for development, reproduction, and tissue repair, whereas
pathological angiogenesis leads to aberrant neovascularization
due to uncontrolled EC activity and contributes to ischemic
cardiovascular disease, rheumatoid arthritis, and cancer
(Carmeliet, 2000). The plaque angiogenesis is of functional
significance in atherosclerosis (Moulton et al., 2003, 2004),
and occurs more frequently in atheromas of patients with
diabetes and unstable coronary syndromes (Burke et al., 1997).
Antiangiogenic endostatin could thus control the progression of
atherosclerosis by inhibiting plaque angiogenesis (Moulton et al.,
1999; Ren et al., 2002, 2003).
Angiogenesis is controlled by biological and physical
interactions between cells and extracellular matrices.
Biological and mechanical signals integrate with other micro-
environmental cues to control angiogenesis via a dynamic
signaling balance between pro- and anti-angiogenic factors,
while the dominant signaling determines the on and off of the
angiogenic switch (Ren et al., 2006, 2009; Chen et al., 2013; Ren,
2015).
Currently, the majority of the research focuses on pro- and
anti-angiogenic factors to regulate angiogenic switch (Bergers
and Benjamin, 2003). Actually, the Yin and Yang balance between
pro- and anti-angiogenic signaling may control the angiogenic
switch. This dynamic signaling balance could play a critical
role in the regulation of pathophysiological and physiological
angiogenesis. Moreover, the angiogenic receptors may serve as
a pivotal axis to regulate this angiogenic process. The ligand and
receptor interactions are the key to integrating signaling for the
regulation of angiogenic switch. A good example is a yin and
yang balance between antiangiogenic TSP-1 and proangiogenic
VEGF signaling which determines angiogenic switch, and in
which PKD-1 is a key player. PKD-1 functions downstream of
VEGF/PLCγ1 signaling to stimulate angiogenesis. LPA, a lipid
signaling mediator, may suppress CD36 expression via PKD-1
and regulate crosstalk between VEGFR2 and CD36, subsequently
contributing to angiogenic switch (Figure 2). VEGF is essential
for angiogenesis due to its regulation of biological responses
in ECs during development and in disease, while TSP-1-
CD36 signaling could crosstalk with VEGF signaling to control
arteriogenic fate and angiogenic responses.
PKD-1 in VEGF Signaling-Mediated EC
Functions
ECs is a key player in angiogenesis (Ren, 2015). VEGF signaling
in ECs is regulated at multiple levels via three receptor
tyrosine kinases or VEGF receptor 1-3 (VEGFR1-3). VEGF
interactions with VEGFR2/KDR (kinase insert domain receptor)
are critical for normal blood vessel development (Matsumoto
and Claesson-Welsh, 2001; Folkman and Kalluri, 2004) and
FIGURE 2 | Dynamic angiogenic signaling balance and angiogenic
switch. VEGF, as an important angiogenic cytokine, is critical for
proangiogenesis, and proarteriogenesis via activating VEGF receptor 2. VEGF
signaling via VEGF receptor 2 can activate PKD-1 pathway via PLCγ1 to
stimulate MAPK/Erk1/2 and PI3K/Akt activation. However, oncogenes, such
as ras and myc or tumor suppressor gene p53 down-regulate or up-regulate
TSP-1 expression, and affect TSP-1 interaction with the CD36 receptor,
altering the activities of Fyn, p38/JNK, and PI3K/Akt kinases. This interaction
may produce disturbances in the dynamic signaling balance between
angiogenesis stimulators and inhibitors. The dominant signaling will determine
the angiogenic switch. LPA also activates PKD-1 signaling to suppress CD36
transcription to tip the signaling balance to VEGF-mediated proangiogenic and
proarteriogenic responses. Inhibition of CD36 expression and its
anti-angiogenic signaling can prime VEGF signaling for turning on the
proangiogenic and proarteriogenic switch for angiogenesis and arteriogenesis.
deregulates in pathological conditions (Wong et al., 2001;
Ferrara et al., 2003). VEGFR-2-mediated VEGF signaling is also
important in proangiogenic responses, including EC migration,
proliferation and tubulogenesis, the key biological processes in
angiogenesis (Wang, 2006; Evans et al., 2008).
PKD-1 signaling plays a key role in those processes in addition
to its roles in regulation of EC survival, trafficking and immune
response (Prigozhina andWaterman-Storer, 2004; Yeaman et al.,
2004; Wang, 2006; Eiseler et al., 2007; von Wichert et al., 2008).
VEGF activates PKD-1 via the VEGFR2/PLCγ/PKCα pathway,
promoting Erk activation andDNA synthesis for EC proliferation
(Wong and Jin, 2005). PKD-1 phosphorylation at tyrosine 463 by
VEGF can activate PLCγ to stimulate proangiogenic responses
(Qin et al., 2006) and activate Erk1/2 signaling (Kohlenberg et al.,
2013), implicating its function in arterial differentiation (Lawson
et al., 2003; Hong et al., 2006; Ren et al., 2015).
PKD-1 regulates collagen I-induced vascular morphogenesis
via modulating GSK3β activity and integrin α(2)β(1) trafficking
(Shin et al., 2012), whereas PKD-1-mediated integrin αvβ3
trafficking contributes to the angiogenic process by integrating
and coordinating EC activity (di Blasio et al., 2010). These
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studies suggest that this kinase mediates the bidirectional
communication between VEGFR and integrins. Furthermore,
PKD-1 regulates VEGF-mediated host inflammatory responses
and could lead to inflammatory angiogenesis. PKD-1 signaling
is associated with VEGF-induced expression of proinflammatory
cytokines via VEGFR2 including interleukin (IL)-6, CXC
chemokines IL-8, and growth-related oncogene-alpha (GRO-
alpha; Hao et al., 2009a). Additionally, PKD-1 interacts with
heat shock proteins (HSPs) to regulate angiogenesis. PKC-
mediated PKD-1 signaling regulates VEGF-induced HSP
27 phosphorylation at phosphorylation site serine 82 and
tubulogenesis in HUVECs (Evans et al., 2008). Recently, PKD-1
was shown to activate endothelial nitric oxide synthase and
orchestrate mammalian vascular tone through phosphorylation,
concomitantly increasing NO synthesis. Inhibition of the
kinase activity in mice abolishes VEGF-induced vasodilatation,
indicating that PKD-1 is the key to transducing VEGF
signaling for VEGF-induced vasodilatation (Aicart-Ramos
et al., 2014). These studies suggest that PKD-1 signaling
may regulate EC cross-talking with other cell types, such
as vascular smooth muscle cells, via producing signaling
molecules in the tissue microenvironments. Interestingly, the
isoform PKD2 also regulates proliferation and migration in
HUVECs, the two important process of angiogenesis, and
this may be mediated by modulation of the expression of
VEGFR-2 and fibroblast growth factor receptor-1 (Hao et al.,
2009b).
PKD Signaling in Tumor Angiogenesis
Tumor angiogenesis is critical, not only in rapidly growing
macroscopic tumors, but also in microscopic premalignant
phase of neoplastic progression, and thus is considered as an
integral hallmark of cancer (Hanahan and Weinberg, 2011).
Emerging studies have begun to focus on PKD functions in tumor
angiogenesis.
PKDs regulate both hypoxia-induced VEGF
expression/secretion by the tumor cells and VEGF- stimulated
angiogenesis, which are essential for the malignant progression
of tumors. Studies show that PKD-1 promotes anchorage-
independent growth, invasion, and angiogenesis in human
pancreatic cancer including PDAC (Guha et al., 2010; Ochi et al.,
2011). In a zebrafish/tumor xenograft model, this kinase is shown
to promote angiogenesis and malignant progression (Hollenbach
et al., 2013). Our study implicates that diet-induced obesity may
promote tumor progression via LPA/PKD-1 signaling-mediated
angiogenesis (Dong et al., 2015). Interestingly, PKD-1 signaling
appears to regulate tumor angiogenesis and is implicated in
tumor arteriogenesis as it may regulate CD36 expression and
vascular remodeling in the tumormicroenvionment (Kohlenberg
et al., 2013).
The PKD-2 also mediates production of various angiogenic
factors in human pancreatic cancer cells and stimulates the
angiogenic response of the host vasculature (Azoitei et al., 2010).
Moreover, this isoform regulates tumor cell communication with
ECs in gastrointestinal tumors and glioblastomas and promotes
tumor growth. Mechanistically, PKD-2 integrates signals from
hypoxia and HSP90 pathways in the NF-κB/VEGF signaling
axis to stimulate angiogenesis and malignant progression
(Azoitei et al., 2014). PKD2 is also able to promote pancreatic
cancer cell invasion in three-dimensional extracellular matrix
cultures by stimulating expression and secretion of matrix
metalloproteinases 7 and 9 (MMP7/9) whereas MMP9 stimulates
PKD2-mediated tumor angiogenesis by releasing extracellular
matrix-bound VEGF and increasing its bioavailability (Wille
et al., 2014).
SUMMARY AND PROSPECTIVE
PKD-1 regulates the expression of a variety of angiogenic
genes. Interestingly, LPA/PKD-1 signaling suppresses CD36
transcription and reprograms MVECs for arteriogenic gene
expression via a nuclear HDAC7-FoxO1 complex, implicating
microvascular remodeling and tumor arteriogenesis (Kohlenberg
et al., 2013; Ren et al., 2015). This not only indicates the
plasticity of adult ECs but also suggests the role of PKD-1 in EC
heterogeneity (Aird, 2012; Ren, 2015). The PKD-FoxO1 signaling
axis may thus function as a molecular link for a dynamic balance
between pro- and anti-angiogenic signaling by controlling EC
CD36 transcription, possibly regulating arteriogenesis via this
axis. Activation of this pathway in vivo may promote vascular
remodeling and the functional stability of the arterial networks
(Ren et al., 2016a). The precise mechanisms and functional
consequences are worthy of future investigation.
Furthermore, PKD-1 signaling is essential for VEGF
signaling-mediated angiogenic functions and is implicated in
tumor arteriogenesis. VEGF signaling is regulated by the tight
control of intracellular VEGFR2 localization (Bhattacharya
et al., 2005; Lanahan et al., 2010). VEGF induces PKD-1
signaling and angiogenesis via regulation of αvβ3 integrin
recycling (Woods et al., 2004; White et al., 2007; di Blasio et al.,
2010). Therefore, PKD-1 signaling might regulate VEGFR-2
trafficking, an important process of VEGF signaling and of
arterial morphogenesis (Lanahan et al., 2010; Simons, 2012)
via cross-talking with integrin αvβ3 and CD36, subsequently
turning on angiogenic switch for arterial differentiation
of ECs to promote arteriogenesis. ECs is essential for
developmental and adult arteriogenesis (Ren et al., 2010;
Simons and Eichmann, 2015) and EC PKD-1 signaling is
essential for improving tissue perfusion through proarteriogenic
reprogramming in the ischemic conditions(Ren et al., 2016b).
It is important to understand how PKD-1 signaling interacts
with FoxO1 and histone deacetylases to initiate an epigenetic
and transcriptional program and control arteriogenic gene
transcription and morphogenesis. This understanding will
provide insight into finding new and effective therapeutic
targets and strategies against cardiovascular disease, cancer, and
obesity.
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